GlaxoSmithKline reportedly investigating corruption allegations in UAE

GlaxoSmithKline, Britain's biggest pharmaceutical group, said it was looking into allegations of corruption in the United Arab Emirates.

The drugmaker, which was hit by a record $489m (£304.26m) fine for corruption in China last month, said the investigation began following allegations of improper payments set out in a whistleblower’s email sent to its top management on Monday.

“As we have already said, we are undertaking an investigation into our operations in the Middle East following complaints made previously. This investigation continues and these specific claims were already being investigated as part of this process,” a GSK spokesman said.